Regulating AI in drug discovery: What FDA, EMA and ICH guidance means for pharma R&D
Regulatory bodies including the FDA, EMA, and the International Council for Harmonisation have issued or are developing guidance on the use of artificial intelligence in pharmaceutical research and drug discovery. The frameworks aim to set expectations for how AI tools are validated, documented, and overseen when used in the drug development pipeline.
Why this matters: AI is now helping decide which drug candidates get pursued and which get dropped. That means it is influencing what medicines get developed and, eventually, what reaches patients. Regulators are trying to catch up. The core issue is accountability: if an AI model shapes a critical research decision and something goes wrong, who is responsible? Guidance from FDA, EMA, and ICH starts to answer that. How well pharma companies actually follow it, and how rigorously regulators enforce it, is what will matter in practice.
Who should care: Lawyers · Compliance · General readers · AI governance · Policy
This summary is AI-assisted and may contain errors. It is an original briefing to help you gauge significance quickly — not a reproduction of the source. Always read the linked original before relying on it. See our methodology.